BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...
BeyondSpring
Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...
NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...